IHE publishes today the third sub-report in a report series on cancer care and access to cancerdrugs in Asia-Pacific.
This report describes patient access to innovative cancer drugs. It shows that there is a big gap between the number of innovative drugs with regulatoryapproval and those with reimbursementapproval. Almost 1 million patient life years are lost for every year of delay in reimbursement of 10 innovative cancer drug-indications across Asia-Pacific.”
Patient access to innovative cancer drugs in Asia-Pacific
IHE Report 2021:3e, IHE: Lund, Sweden